New injection tested for weight loss and diabetes control
NCT ID NCT04838405
Summary
This early-stage study tested the safety and effects of a new injectable drug called CT-388. It involved 129 overweight or obese adults, some with type 2 diabetes. Researchers measured how the body processes the drug and its impact on weight and blood sugar levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carmot Clinical Research Unit 101
Perth, Western Australia, 6009, Australia
-
Carmot Clinical Research Unit 105
Monterrey, Nuevo León, 66260, Mexico
Conditions
Explore the condition pages connected to this study.